Puma Biotechnology Inc (PBYI.OQ)
16 Jan 2018
Thu, Jan 11 2018
BRIEF-Puma Biotechnology Intends To Modify Characteristics Summary In Neratinib Marketing Authorization Application
* PUMA BIOTECHNOLOGY INC SAYS IT MET WITH COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE SCIENTIFIC ADVISORY GROUP ON ONCOLOGY
BRIEF-Daiichi Sankyo And Puma Biotechnology To Collaborate With Major Cancer Center In HER2-Mutated Cancer
* DAIICHI SANKYO AND PUMA BIOTECHNOLOGY ANNOUNCE RESEARCH COLLABORATION WITH MAJOR CANCER CENTER IN HER2-MUTATED CANCER Source text for Eikon: Further company coverage:
* PUMA BIOTECHNOLOGY ANNOUNCES POSITIVE OUTCOME OF EUROPEAN OPPOSITION PROCEEDINGS
BRIEF-PUMA BIOTECHNOLOGY, SPECIALISED THERAPEUTICS ASIA AGREE TO COMMERCIALIZE NERLYNX IN SOUTH EAST ASIA
* PUMA BIOTECHNOLOGY AND SPECIALISED THERAPEUTICS ASIA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN AUSTRALIA, NEW ZEALAND AND SOUTH EAST ASIA
* Puma Biotechnology reports third quarter 2017 financial results
* Puma Biotechnology secures $100 million term loan from Silicon Valley Bank and Oxford Finance
BOSTON, Nov 2 A former Puma Biotechnology Inc executive pleaded guilty on Thursday to U.S. charges that he traded on inside information ahead of announcements by the biopharmaceutical company about a drug it was developing to treat breast cancer.
* Puma Biotechnology reports second quarter 2017 financial results
The U.S. Food and Drug Administration (FDA) on Monday approved Puma Biotechnology Inc's experimental breast cancer drug that lowers the risk of the disease returning after initial treatment.
July 17 The U.S. Food and Drug Administration (FDA) on Monday approved Puma Biotechnology Inc's experimental breast cancer drug that lowers the risk of the disease returning after initial treatment.